OncoMatch/Clinical Trials/NCT07104331
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Is NCT07104331 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies nab-Sirolimus for epithelioid hemangioendothelioma (ehe).
Treatment: nab-Sirolimus — This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. The primary objective is to determine ORR by RECIST v1.1 of nab-sirolimus in patients with EHE who require systemic treatment.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Platelets >75,000μl; ANC >1500μl; Hgb >9g/dl
Kidney function
Creatinine <1.5 x ULN or measured CrCl of >30ml/m2/1.73 m2
Liver function
Total bilirubin <2 x ULN; AST/ALT <3 x ULN
Platelets >75,000μl; ANC >1500μl; Hgb >9g/dl; Creatinine <1.5 x ULN or measured CrCl of >30ml/m2/1.73 m2; Total bilirubin <2 x ULN; AST/ALT <3 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Stanford, California
- University of Colorado · Aurora, Colorado
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Washington University St. Louis · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify